piperacillin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 2187 61477-96-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • piperacillin hydrate
  • piperacillin
  • piperacillin sodium
  • pipracil
  • piperacillin sodium salt
Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.
  • Molecular weight: 517.56
  • Formula: C23H27N5O7S
  • CLOGP: 1.36
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 3
  • TPSA: 156.43
  • ALOGS: -3.64
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
14 g P
14 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 714.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 71 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 772.85 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.27 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.50 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.96 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1981 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sepsis 102.44 18.36 120 9348 153003 63326551
Pyrexia 100.48 18.36 218 9250 470260 63009294
Thrombocytopenia 97.04 18.36 116 9352 151041 63328513
Toxic epidermal necrolysis 93.54 18.36 54 9414 25280 63454274
Acute kidney injury 75.19 18.36 138 9330 263277 63216277
Rash maculo-papular 72.49 18.36 50 9418 31846 63447708
Respiratory failure 68.32 18.36 80 9388 101778 63377776
Septic shock 65.30 18.36 64 9404 66565 63412989
Multiple organ dysfunction syndrome 64.17 18.36 59 9409 56693 63422861
Pancytopenia 61.49 18.36 74 9394 96859 63382695
Renal failure 56.11 18.36 78 9390 117574 63361980
Disseminated intravascular coagulation 55.79 18.36 35 9433 19016 63460538
Fatigue 54.10 18.36 33 9435 887995 62591559
Eosinophilia 52.47 18.36 36 9432 22720 63456834
Platelet count decreased 50.96 18.36 74 9394 116048 63363506
Excessive eye blinking 50.67 18.36 15 9453 1265 63478289
Dermatitis exfoliative generalised 48.29 18.36 19 9449 3788 63475766
Drug reaction with eosinophilia and systemic symptoms 47.92 18.36 40 9428 33796 63445758
Urinary tract obstruction 46.48 18.36 16 9452 2192 63477362
Tubulointerstitial nephritis 44.74 18.36 31 9437 19872 63459682
Leukopenia 42.58 18.36 55 9413 77235 63402319
Arthralgia 40.85 18.36 17 9451 569693 62909861
Tonic clonic movements 40.61 18.36 13 9455 1422 63478132
Pseudomembranous colitis 37.61 18.36 15 9453 3097 63476457
Febrile neutropenia 37.47 18.36 65 9403 118384 63361170
Blood creatinine increased 37.10 18.36 55 9413 87789 63391765
Rash morbilliform 36.65 18.36 15 9453 3310 63476244
Drug ineffective 35.31 18.36 64 9404 1044701 62434853
Haemoglobin decreased 35.00 18.36 71 9397 145414 63334140
Joint swelling 34.96 18.36 4 9464 327662 63151892
Drug intolerance 34.94 18.36 3 9465 308658 63170896
Headache 33.87 18.36 27 9441 633214 62846340
Haemolytic anaemia 33.20 18.36 20 9448 10105 63469449
Biloma 32.40 18.36 6 9462 61 63479493
Heparin-induced thrombocytopenia 32.03 18.36 15 9453 4567 63474987
Alopecia 31.68 18.36 6 9462 337530 63142024
Stevens-Johnson syndrome 30.26 18.36 27 9441 24923 63454631
Agranulocytosis 30.09 18.36 27 9441 25107 63454447
Abdominal discomfort 29.49 18.36 6 9462 320879 63158675
Acute generalised exanthematous pustulosis 29.04 18.36 19 9449 11080 63468474
Hepatic function abnormal 27.96 18.36 31 9437 37111 63442443
Haemophagocytic lymphohistiocytosis 27.34 18.36 18 9450 10609 63468945
Transplant rejection 27.10 18.36 18 9450 10762 63468792
Nephropathy toxic 26.71 18.36 17 9451 9462 63470092
Peripheral swelling 26.55 18.36 4 9464 265938 63213616
Neutropenia 26.26 18.36 71 9397 174934 63304620
Dizziness 26.03 18.36 16 9452 429909 63049645
Pleural effusion 25.45 18.36 48 9420 93162 63386392
Linear IgA disease 24.77 18.36 9 9459 1442 63478112
Product dose omission issue 24.63 18.36 3 9465 234310 63245244
Anaemia 24.12 18.36 97 9371 293333 63186221
Aspergillus infection 24.02 18.36 15 9453 8078 63471476
Leukocytosis 23.70 18.36 24 9444 25911 63453643
Autoimmune haemolytic anaemia 23.03 18.36 12 9456 4589 63474965
Hypokalaemia 23.00 18.36 49 9419 103755 63375799
Ejection fraction decreased 22.88 18.36 22 9446 22310 63457244
Weight increased 21.74 18.36 6 9462 260786 63218768
Prothrombin time prolonged 21.73 18.36 15 9453 9549 63470005
Unresponsive to stimuli 21.71 18.36 26 9442 33790 63445764
Platelet count increased 21.15 18.36 19 9449 17692 63461862
Product contamination microbial 20.19 18.36 5 9463 214 63479340
Hypotension 19.96 18.36 87 9381 272517 63207037
Fall 19.38 18.36 18 9450 392316 63087238
Systemic lupus erythematosus 18.98 18.36 4 9464 208914 63270640
Cytarabine syndrome 18.85 18.36 4 9464 85 63479469
Small intestinal obstruction 18.67 18.36 18 9450 18319 63461235
Epidermolysis 18.59 18.36 6 9462 673 63478881
Large intestine perforation 18.56 18.36 13 9455 8469 63471085
Mental status changes 18.47 18.36 26 9442 39573 63439981

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tubulointerstitial nephritis 105.10 15.58 74 12024 20950 34923883
Acute kidney injury 100.99 15.58 281 11817 304707 34640126
Thrombocytopenia 94.87 15.58 183 11915 156064 34788769
Sepsis 78.68 15.58 176 11922 166385 34778448
Pyrexia 77.85 15.58 272 11826 332741 34612092
Drug reaction with eosinophilia and systemic symptoms 72.12 15.58 72 12026 32940 34911893
Cholestasis 53.80 15.58 56 12042 26892 34917941
Eosinophilia 51.47 15.58 54 12044 26168 34918665
Rash maculo-papular 49.54 15.58 55 12043 28396 34916437
Disseminated intravascular coagulation 48.40 15.58 48 12050 21768 34923065
Multiple organ dysfunction syndrome 46.71 15.58 90 12008 76476 34868357
Clostridial infection 45.16 15.58 23 12075 3604 34941229
Toxic epidermal necrolysis 43.23 15.58 45 12053 21601 34923232
Renal tubular necrosis 41.43 15.58 38 12060 15642 34929191
Agranulocytosis 41.38 15.58 46 12052 23775 34921058
Neutropenia 40.76 15.58 133 11965 156645 34788188
Rash 40.30 15.58 168 11930 222584 34722249
Septic shock 39.67 15.58 81 12017 71753 34873080
Dizziness 36.51 15.58 15 12083 218506 34726327
Renal failure 35.96 15.58 113 11985 130444 34814389
Respiratory failure 34.64 15.58 99 11999 108473 34836360
Stevens-Johnson syndrome 34.12 15.58 37 12061 18602 34926231
Choroiditis 32.03 15.58 13 12085 1202 34943631
Heparin-induced thrombocytopenia 31.01 15.58 21 12077 5574 34939259
Gamma-glutamyltransferase increased 30.85 15.58 44 12054 29187 34915646
Fatigue 30.49 15.58 51 12047 370602 34574231
Clostridium difficile colitis 30.15 15.58 32 12066 15698 34929135
Blood alkaline phosphatase increased 30.10 15.58 45 12053 31130 34913703
Congenital pneumonia 30.07 15.58 7 12091 95 34944738
Nephropathy toxic 28.48 15.58 28 12070 12560 34932273
Death 28.14 15.58 60 12038 397989 34546844
Blood creatinine increased 26.86 15.58 83 12015 94893 34849940
Pancytopenia 26.76 15.58 83 12015 95074 34849759
Febrile neutropenia 25.30 15.58 104 11994 136745 34808088
Autoimmune haemolytic anaemia 25.22 15.58 17 12081 4479 34940354
Alanine aminotransferase increased 25.09 15.58 73 12025 80742 34864091
Arthralgia 24.83 15.58 14 12084 170027 34774806
Blood bilirubin increased 24.54 15.58 46 12052 38250 34906583
Aspartate aminotransferase increased 23.76 15.58 64 12034 67719 34877114
Transplant rejection 23.44 15.58 23 12075 10288 34934545
Pneumonia staphylococcal 23.36 15.58 14 12084 3010 34941823
Subclavian artery occlusion 23.36 15.58 6 12092 125 34944708
Nephritis 23.34 15.58 13 12085 2438 34942395
Acute respiratory distress syndrome 22.98 15.58 36 12062 25933 34918900
Hepatic failure 22.78 15.58 42 12056 34489 34910344
Chondritis 21.81 15.58 6 12092 164 34944669
Device related infection 21.28 15.58 28 12070 17209 34927624
Rash erythematous 21.23 15.58 34 12064 24943 34919890
Haemodialysis 21.22 15.58 22 12076 10504 34934329
Skin exfoliation 20.19 15.58 35 12063 27397 34917436
Dialysis 20.07 15.58 22 12076 11186 34933647
Weight increased 19.89 15.58 4 12094 93029 34851804
Organ failure 19.66 15.58 11 12087 2080 34942753
Drug eruption 19.60 15.58 29 12069 19869 34924964
Interstitial lung disease 19.33 15.58 58 12040 65224 34879609
Headache 18.98 15.58 25 12073 200610 34744223
Hepatic function abnormal 18.78 15.58 45 12053 44318 34900515
Weight decreased 18.78 15.58 20 12078 176281 34768552
Anaphylactic reaction 18.49 15.58 37 12061 32264 34912569
Platelet count decreased 18.32 15.58 86 12012 119631 34825202
Leukopenia 17.82 15.58 55 12043 62801 34882032
Petechiae 17.77 15.58 19 12079 9399 34935434
Dermatitis exfoliative 17.36 15.58 16 12082 6623 34938210
Hepatic cytolysis 17.05 15.58 23 12075 14473 34930360
Abdominal abscess 17.01 15.58 13 12085 4162 34940671
Renal impairment 16.80 15.58 71 12027 94442 34850391
Blister 16.60 15.58 29 12069 22829 34922004
Muscle spasms 16.51 15.58 3 12095 74998 34869835
Antibiotic level below therapeutic 16.23 15.58 4 12094 70 34944763
Intraocular pressure increased 16.11 15.58 14 12084 5369 34939464
Respiratory distress 15.99 15.58 37 12061 35628 34909205
Hypotension 15.94 15.58 131 11967 221518 34723315
Scar pain 15.92 15.58 4 12094 76 34944757
Neuralgic amyotrophy 15.63 15.58 5 12093 232 34944601

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 162.67 16.11 362 17812 519042 79207172
Thrombocytopenia 148.10 16.11 237 17937 265022 79461192
Pyrexia 146.17 16.11 410 17764 678299 79047915
Sepsis 138.60 16.11 232 17942 269196 79457018
Tubulointerstitial nephritis 138.48 16.11 94 18080 38141 79688073
Toxic epidermal necrolysis 116.66 16.11 90 18084 44491 79681723
Drug reaction with eosinophilia and systemic symptoms 112.80 16.11 103 18071 64141 79662073
Rash maculo-papular 102.55 16.11 92 18082 55986 79670228
Septic shock 96.39 16.11 129 18045 122672 79603542
Eosinophilia 88.10 16.11 77 18097 45268 79680946
Renal failure 82.56 16.11 157 18017 200811 79525403
Multiple organ dysfunction syndrome 80.45 16.11 117 18057 120129 79606085
Fatigue 79.40 16.11 58 18116 929669 78796545
Pancytopenia 67.44 16.11 129 18045 165616 79560598
Arthralgia 66.02 16.11 24 18150 571779 79154435
Disseminated intravascular coagulation 65.90 16.11 59 18115 35783 79690431
Respiratory failure 64.23 16.11 133 18041 180778 79545436
Dizziness 59.25 16.11 23 18151 526418 79199796
Clostridial infection 59.23 16.11 28 18146 5686 79720528
Agranulocytosis 58.06 16.11 61 18113 44969 79681245
Heparin-induced thrombocytopenia 55.81 16.11 32 18142 9650 79716564
Transplant rejection 54.70 16.11 41 18133 19396 79706818
Platelet count decreased 54.33 16.11 130 18044 194534 79531680
Stevens-Johnson syndrome 52.18 16.11 54 18120 39112 79687102
Autoimmune haemolytic anaemia 51.82 16.11 29 18145 8351 79717863
Headache 51.63 16.11 44 18130 653728 79072486
Nephropathy toxic 50.74 16.11 40 18134 20379 79705835
Joint swelling 50.69 16.11 4 18170 288642 79437572
Neutropenia 50.35 16.11 162 18012 287548 79438666
Cholestasis 49.13 16.11 60 18114 52049 79674165
Renal tubular necrosis 47.58 16.11 42 18132 24997 79701217
Febrile neutropenia 46.87 16.11 137 18037 230862 79495352
Peripheral swelling 46.61 16.11 4 18170 269613 79456601
Product dose omission issue 44.69 16.11 3 18171 247534 79478680
Weight increased 43.18 16.11 6 18168 277380 79448834
Leukopenia 42.90 16.11 87 18087 116426 79609788
Urinary tract obstruction 42.30 16.11 21 18153 4744 79721470
Acute generalised exanthematous pustulosis 41.16 16.11 33 18141 17221 79708993
Nasopharyngitis 40.69 16.11 5 18169 253876 79472338
Clostridium difficile colitis 40.31 16.11 43 18131 32240 79693974
Pseudomembranous colitis 39.91 16.11 21 18153 5353 79720861
Blood creatinine increased 39.48 16.11 100 18074 154957 79571257
Alopecia 38.48 16.11 4 18170 231351 79494863
Drug intolerance 38.21 16.11 7 18167 264112 79462102
Rash 37.18 16.11 242 17932 578116 79148098
Fall 37.03 16.11 34 18140 487595 79238619
Excessive eye blinking 36.61 16.11 14 18160 1687 79724527
Dialysis 35.14 16.11 31 18143 18431 79707783
Abdominal discomfort 33.48 16.11 8 18166 250719 79475495
Acute respiratory distress syndrome 32.57 16.11 45 18129 44022 79682192
Choroiditis 32.01 16.11 12 18162 1369 79724845
Dermatitis exfoliative generalised 31.56 16.11 20 18154 7221 79718993
Weight decreased 30.39 16.11 22 18152 355176 79371038
Nephritis 29.98 16.11 16 18158 4198 79722016
Prothrombin time prolonged 29.45 16.11 27 18147 16872 79709342
Drug ineffective 29.29 16.11 137 18037 1080776 78645438
Hypotension 28.71 16.11 185 17989 440132 79286082
Hepatic function abnormal 28.59 16.11 56 18118 73051 79653163
Staphylococcal sepsis 28.57 16.11 25 18149 14701 79711513
Petechiae 28.56 16.11 29 18145 20536 79705678
Haemoglobin decreased 28.47 16.11 113 18061 222006 79504208
Renal impairment 27.69 16.11 89 18085 157694 79568520
Haemolytic anaemia 26.35 16.11 26 18148 17794 79708420
Tonic clonic movements 26.28 16.11 12 18162 2252 79723962
Rash erythematous 26.01 16.11 47 18127 57722 79668492
Interstitial lung disease 25.96 16.11 70 18104 112530 79613684
Intravascular haemolysis 25.95 16.11 9 18165 821 79725393
Haemodialysis 25.92 16.11 26 18148 18142 79708072
Linear IgA disease 25.45 16.11 13 18161 3119 79723095
Enterococcal infection 25.32 16.11 24 18150 15636 79710578
Hepatic failure 25.30 16.11 48 18126 61164 79665050
Blood alkaline phosphatase increased 25.18 16.11 49 18125 63615 79662599
Biloma 24.77 16.11 6 18168 151 79726063
Pain in extremity 24.71 16.11 28 18146 364510 79361704
Musculoskeletal stiffness 24.54 16.11 5 18169 175003 79551211
Rash morbilliform 24.37 16.11 16 18158 6134 79720080
Drug abuse 24.20 16.11 4 18170 162687 79563527
Subclavian artery occlusion 24.16 16.11 6 18168 168 79726046
Aspartate aminotransferase increased 24.14 16.11 78 18096 138563 79587651
Clostridium difficile infection 23.53 16.11 38 18136 42647 79683567
Aplasia pure red cell 23.15 16.11 17 18157 7793 79718421
Antibiotic level above therapeutic 23.05 16.11 8 18166 732 79725482
Leukocytosis 23.02 16.11 38 18136 43417 79682797
Aspergillus infection 23.00 16.11 25 18149 19136 79707078
Pleural effusion 22.87 16.11 79 18095 145183 79581031
Antibiotic level below therapeutic 22.67 16.11 5 18169 82 79726132
Blood bilirubin increased 22.65 16.11 48 18126 66184 79660030
Dermatitis exfoliative 22.26 16.11 19 18155 10810 79715404
Encephalopathy 22.08 16.11 48 18126 67349 79658865
White blood cell count increased 22.04 16.11 51 18123 74582 79651632
Staphylococcal infection 22.00 16.11 44 18130 58251 79667963
Respiratory distress 21.98 16.11 44 18130 58295 79667919
Renal injury 21.93 16.11 23 18151 16904 79709310
Swelling 21.91 16.11 11 18163 216700 79509514
Pneumonia 21.81 16.11 238 17936 660008 79066206
Skin exfoliation 21.29 16.11 42 18132 55058 79671156
Insomnia 21.20 16.11 15 18159 245155 79481059
Pain 20.95 16.11 86 18088 703716 79022498
Neutrophilic dermatosis 20.80 16.11 7 18167 583 79725631
Systemic candida 20.79 16.11 15 18159 6691 79719523
Muscle spasms 20.68 16.11 7 18167 174723 79551491
Inappropriate schedule of product administration 20.52 16.11 3 18171 133625 79592589
Hepatic cytolysis 20.47 16.11 28 18146 27123 79699091
Haemophagocytic lymphohistiocytosis 20.34 16.11 25 18149 21812 79704402
Immune effector cell-associated neurotoxicity syndrome 20.26 16.11 14 18160 5834 79720380
Alanine aminotransferase increased 20.25 16.11 82 18092 162488 79563726
Toxic skin eruption 19.93 16.11 25 18149 22268 79703946
Pathogen resistance 19.50 16.11 20 18154 14322 79711892
Chondritis 19.49 16.11 5 18169 160 79726054
Toxicity to various agents 19.40 16.11 42 18132 421498 79304716
Contusion 19.36 16.11 5 18169 148771 79577443
Mixed liver injury 19.16 16.11 15 18159 7563 79718651
Depression 19.09 16.11 13 18161 216777 79509437
Extravasation blood 18.87 16.11 6 18168 418 79725796
Neutrophil count decreased 18.33 16.11 55 18119 93904 79632310
Sinusitis 18.20 16.11 11 18163 195490 79530724
Acanthosis 17.91 16.11 6 18168 493 79725721
Pneumonia pseudomonal 17.82 16.11 13 18161 5898 79720316
Abdominal abscess 17.78 16.11 14 18160 7113 79719101
Blood culture positive 17.75 16.11 15 18159 8414 79717800
Pneumonia staphylococcal 17.67 16.11 12 18162 4862 79721352
Purpura 17.62 16.11 22 18152 19505 79706709
Injection site pain 17.60 16.11 4 18170 129834 79596380
Drug eruption 17.59 16.11 34 18140 43901 79682313
Oliguria 17.38 16.11 20 18154 16289 79709925
Anaphylactic reaction 17.27 16.11 50 18124 83693 79642521
Organ failure 17.23 16.11 11 18163 4022 79722192
Hepatocellular injury 16.87 16.11 35 18139 47558 79678656
Gamma-glutamyltransferase increased 16.85 16.11 38 18136 54642 79671572
Mental status changes 16.83 16.11 43 18131 66916 79659298
White blood cell count decreased 16.75 16.11 86 18088 188202 79538012
Neuralgic amyotrophy 16.70 16.11 5 18169 285 79725929
Hyperbilirubinaemia 16.58 16.11 24 18150 24494 79701720
Cytarabine syndrome 16.46 16.11 4 18170 102 79726112
Skin oedema 16.43 16.11 8 18166 1733 79724481
Malaise 16.41 16.11 57 18117 489812 79236402
Chronic hepatitis C 16.33 16.11 6 18168 647 79725567
Bone marrow failure 16.29 16.11 36 18138 51071 79675143
Gait disturbance 16.28 16.11 14 18160 207492 79518722
Feeling abnormal 16.21 16.11 8 18166 159191 79567023

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CA12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Penicillins with extended spectrum
ATC J01CR05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Combinations of penicillins, incl. beta-lactamase inhibitors
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Infection due to Pseudomonas aeruginosa indication 11218009
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Streptococcal septicemia indication 29577008
Acute gonococcal urethritis indication 29864006
Postoperative infection indication 33910007
Pneumonia due to Pseudomonas indication 41381004
Peritonitis indication 48661000
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Acute gonococcal endometritis indication 65295003 DOID:7527
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Bacterial infection due to Serratia indication 71120004
Rhinoscleroma indication 72409005 DOID:11336
Appendicitis indication 74400008 DOID:8337
Abdominal abscess indication 75100008
Septicemia due to Bacteroides indication 79587009
Septicemia due to Serratia indication 82091000
Infection of bone indication 111253001
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Proteus septicemia indication 300986008
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Septicemia due to enterococcus indication 310669007
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Nosocomial pneumonia indication 425464007
Sepsis due to Pseudomonas indication 448813005
Sepsis due to Gram negative bacteria indication 449082003
Urinary tract infection caused by Klebsiella indication 369001000119100
Skin and Skin Structure Bacteroides Fragilis Infection indication
E. Coli Appendicitis indication
Bacteroides Pneumonia indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Bacteroides Peritonitis indication
Skin and Skin Structure Enterococcus Infection indication
Prevention of Perioperative Infection indication
Pseudomonas Aeruginosa Urinary Tract Infection indication
Bacteroides Pelvic Inflammatory Disease indication
Bacteroides Pelvic Cellulitis indication
Bacteroides Endometritis indication
E. Coli Peritonitis indication
Pseudomonas Aeruginosa Joint Infection indication
Bacteroides Complicated Appendicitis indication
Enterococcus Urinary Tract Infection indication
E. Coli Pelvic Inflammatory Disease indication
Skin and Skin Structure Serratia Infection indication
Bacteroides Appendicitis indication
Neisseria Gonorrhea Pelvic Cellulitis indication
Enterococcus Peritonitis indication
Cesarean Section Infection Prevention indication
Vaginal Hysterectomy Infection Prevention indication
Enterococcus Pelvic Inflammatory Disease indication
Bacteroides Osteomyelitis indication
Infection Prevention for GI Surgery indication
Enterococcus Joint Infection indication
Clostridium Peritonitis indication
Complicated Skin and Skin Structure Infection indication
Inflammatory Disease of Female Pelvic Organs indication
Pseudomonas Aeruginosa Osteomyelitis indication
Peptostreptococcus Pelvic Inflammatory Disease indication
Complicated Proteus UTI indication
Staphylococcus Nosocomial Pneumonia indication
Skin and Skin Structure Acinetobacter Infection indication
Bacteroides Joint Infection indication
Enterococcus Complicated UTI indication
Skin and Skin Structure Proteus Infection indication
Enterobacter Pneumonia indication
E. Coli Complicated Appendicitis indication
E. Coli Endometritis indication
Diabetic Foot Infection indication
Enterococcus Osteomyelitis indication
Enterococcus Endometritis indication
Complicated UTI with Pseudomonas Aeruginosa indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Enterococcus Pelvic Cellulitis indication
Ecthyma gangrenosum off-label use 17732003
Sepsis of the newborn off-label use 206376005
Diverticulitis of gastrointestinal tract off-label use 271366000
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Blood coagulation disorder contraindication 64779008 DOID:1247
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Neutropenic disorder contraindication 303011007 DOID:1227
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.79 acidic
pKa2 12.64 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML;EQ 5MG BASE/ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML;EQ 5MG BASE/ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML ZOSYN IN PLASTIC CONTAINER BAXTER HLTHCARE CORP N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK
Beta-lactamase Enzyme Ki 6.70 CHEMBL
Streptokinase A Enzyme EC50 6.55 WOMBAT-PK

External reference:

IDSource
4019896 VUID
N0000147981 NUI
D00466 KEGG_DRUG
59703-84-3 SECONDARY_CAS_RN
4018917 VANDF
4019896 VANDF
C0031955 UMLSCUI
CHEBI:8232 CHEBI
WPP PDB_CHEM_ID
CHEMBL702 ChEMBL_ID
CHEMBL1200820 ChEMBL_ID
D010878 MESH_DESCRIPTOR_UI
DB00319 DRUGBANK_ID
10921 IUPHAR_LIGAND_ID
X00B0D5O0E UNII
43672 PUBCHEM_CID
203134 RXNORM
1514 MMSL
5304 MMSL
60235 MMSL
d00057 MMSL
002688 NDDF
004832 NDDF
11644000 SNOMEDCT_US
372836004 SNOMEDCT_US
74575000 SNOMEDCT_US
66258-76-2 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 3 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 3 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 3 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 4 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 4 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 4 g INTRAVENOUS NDA 27 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0338-9632 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 29 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0338-9636 INJECTION, SOLUTION 3 g INTRAVENOUS NDA 29 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0338-9638 INJECTION, SOLUTION 4 g INTRAVENOUS NDA 29 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 12 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 12 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 12 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3374 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3374 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3374 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3379 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3379 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3379 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 26 sections